Research programme: pain therapeutics - RaQualia Pharma/XuanZhu Pharma
Latest Information Update: 27 Jul 2016
At a glance
- Originator RaQualia Pharma; XuanZhu Pharma
- Class Analgesics
- Mechanism of Action Ion channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Pain